Abstract
Background: Data sharing from clinical trials can be key to the development and approval of medicines for rare diseases. Many events during the first half of 2013 have contributed to the movement for increased transparency. These include the development of the European Medicines Agency's new data publication policy, the creation of the AllTrials petition and GlaxoSmithKline's choice to sign it, the launch of GlaxoSmithKline's system for access to patient-level clinical trial data and Roche's commitment to create a similar system, the release of results from the Yale University Open Data Access project's first medicine analysis for Medtronic, and the creation of the Reg4All website. Aims/Objectives: This paper summarises major developments in clinical trial transparency between January and June 2013 and analyses the composition of datasets released by GlaxoSmithKline. Methods: GlaxoSmithKline's database of available trials was tabulated and graphs of relevant trial characteristics were produced. Results/Conclusions: Due to current transparency initiatives, it is likely that much more data will be made available over the next few years through systems similar to GlaxoSmithKline's. Although some aspects of GlaxoSmithKline's model could limit its usefulness, the data currently listed is diverse and could be promising for researchers interested in rare disease treatment.
References
1.
An Act to amend the public health service act to establish an office of rare diseases at the national institutes of health, and for other purposes, Pub. L. No. 107-280, 116 Stat. 1988-1991 [2002 Nov 6].
2.
European Parliament and Council Regulation (EC) No 141/2000 of 16 December 1999 on orphan medicinal products. Official Journal L 18 of 22.1.2000.
3.
Marpillat N: Prevalence of rare diseases: bibliographic data; in Kremp O (ed): Orphanet Report Series. Orphanet 2012.
4.
Cassino C, Orfali M, Charnigo RJ, Marsden DL: Rare and orphan diseases challenges: clinical development and clinical practice. J Rare Disorders 2013;1:1-3.
5.
Sardana D, Zhu C, Zhang M, Gudivada RC, Yang L, Jegga AG: Drug repositioning for orphan diseases. Brief Bioinform 2011;12:346-356.
6.
Coté TR, Xu K, Pariser AR: Accelerating orphan drug development. Nat Rev Drug Discov 2010;9:901-902.
7.
Melnikova I: Rare diseases and orphan drugs. Nat Rev Drug Discov 2012;11:267-268.
8.
Ross JS, Krumholz HM: Ushering in a new era of open science through data sharing: the wall must come down. JAMA 2013;309:1355-1356.
9.
Rabesandratana T: Europe. Drug watchdog ponders how to open clinical trial data vault. Science 2013;339:1369-1370.
10.
Knoppers BM: ‘Big' Pharma: from data hoarding to data sharing? (presentation). IRDiRC International Rare Diseases Reseach Consortium Conference: interdisciplinary track: facing the challenges, Dublin, April 2013.
11.
Thomas K: Glaxo opens door to data on research. New York Times, Oct 11, 2012, Sect. B:1.
12.
PR Newswire: Industry group supports uniform approach to transparency of clinical trial data. 2013. http://www.prnewswire.com/news-releases/industry-group-supports-uniform-approach-to-transparency-of-clinical-trial-data-201651151.html (accessed June 25, 2013).
13.
Institute of Medicine: Sharing clinical research data: a workshop. Washington DC, The National Academic Press, 2013.
14.
Ross JS, Mulvey GK, Hines EM, Nissen SE, Krumholz HM: Trial publication after registration in ClinicalTrials.gov: a cross-sectional analysis. PLoS Med 2009;6:e1000144.
15.
Krumholz HM, Ross JS, Gross CP, Emanuel EJ, Hodshon B, Ritchie JD, Low JB, Lehman R: A historic moment for open science: the Yale University Open Data Access project and medtronic. Ann Intern Med 2013;158:910-911.
16.
European Medicines Agency: publication and access to clinical-trial data. http://www.ema.europa.eu/docs/en_GB/document_library/Other/2013/06/WC500144730.pdf (accessed June 27, 2013).
17.
World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. Seoul, World Medical Association, 2008. http://www.wma.net/en/30publications/10policies/b3/17c.pdf (accessed June 25, 2013).
18.
World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. Tokyo, World Medical Association, 2013. http://www.wma.net/fr/20activities/10ethics/10helsinki/15publicconsult/DoH-draft-for-public-consultation_annotated.pdf (accessed July 8, 2013).
19.
Song F, Parekh S, Hooper L, Loke YK, Ryder J, Sutton AJ, Hing C, Kwok CS, Pang C, Harvey I: Dissemination and publication of research findings: an updated review of related biases. Health Technol Assess 2010;14:iii, ix-xi, 1-193.
20.
Couzin-Frankel J: European court wants drug data kept secret. Washington, DC, Science Magazine, 2013. http://news.sciencemag.org/scienceinsider/2013/04/european-court-wants-drug-data-k.html (accessed May 29, 2013).
21.
Hirschler B: Europe's regulator digs in for drug data fight. 2013. http://www.reuters.com/article/2013/04/30/europe-medicines-data-idUSL6N0DH3A520130430 (accessed June 18, 2013).
22.
Dodds-Smith I, Williams A, Townsend E, Mulryne J: Interim relief granted in challenge to EMA's decision to disclose pre-clinical and clinical information from an application for a centralised marketing authorisation. http://www.lexology.com/library/detail.aspx?g=35163111-00a1-461e-a627-ed02addb30ae.
23.
Roche: F. Hoffmann-La Roche Ltd; c2013. Roche launches new process for accessing clinical trial data. 2013. http://www.roche.com/media/media_releases/med-cor-2013-02-26.htm (accessed June 26, 2013).
24.
Kuntz RE: The changing structure of industry-sponsored clinical research: pioneering data sharing and transparency. Ann Intern Med 2013;158:914-915.
25.
International Rare Diseases Research Consortium (IRDiRC): c2013. http://www.irdirc.org/ (accessed July 8, 2013).
26.
European Medicines Agency (EMA): c1995-2013. European medicines agency releases for public consultation its draft policy on the publication and access to clinical-trial data. 2013. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/06/news_detail_001825.jsp&mid=WC0b01ac058004d5c1 (accessed June 27, 2013).
27.
AllTrials: All Trials Registered, All Results Reported: The AllTrials campaign. 2013. http://www.alltrials.net/blog/the-alltrials-campaign/ (accessed June 21, 2013).
28.
GlaxoSmithKline: GSK announces support for AllTrials campaign for clinical data transparency. 2013. http://www.gsk.com/media/press-releases/2013/GSK-announces-support-forAll-Trials-campaign-for-clinical-data-transparency.html (accessed June 25, 2013).
29.
GlaxoSmithKline: GSK gives update on plans to share detailed clinical trial data as part of its commitment to transparency. 2013. http://www.gsk.com/media/press-releases/2013/gsk-gives-update-on-plans-to-share-detailed-clinical-trial-data-.html (accessed June 25, 2013).
30.
Simmonds MC, Brown JVE, Heirs MK, Higgins JPT, Mannion RJ, Rodgers MA, Stewart LA: Safety and effectiveness of recombinant human bone morphogenetic protein-2 for spinal fusion: a meta-analysis of individual-participant data. Ann Intern Med 2013;158:877-889.
31.
Fu R, Selph S, McDonagh M, Peterson K, Tiwari A, Chou R, Helfand M: Effectiveness and harms of recombinant human bone morphogenetic protein-2 in spine fusion: a systematic review and meta-analysis. Ann Intern Med 2013;158:890-902.
32.
Genetic Alliance: Genetic alliance announces registries for all. 2013. http://www.geneticalliance.org/pr.reg4all (accessed June 25, 2013).
33.
U.S. National Institutes of Health: Clinicaltrials.gov. http://clinicaltrials.gov (accessed July 4, 2013).
34.
Mathieu S, Boutron I, Moher D, Altman DG, Ravaud P: Comparison of registered and published primary outcomes in randomized controlled trials. JAMA 2009;302:977-984.
35.
Prayle AP, Hurley MN, Smyth AR: Compliance with mandatory reporting of clinical trial results on clinicaltrials.gov: cross sectional study. BMJ 2012;344:d7373.
36.
Hirschler B: Drugmakers split as demands for open data mount. 2013. http://www.reuters.com/article/2013/05/08/us-summit-data-idUSBRE9470LZ20130508 (accessed June 20, 2013).
37.
Regulation (EC) No 1049/2001 of the European Parliament and of the Council of 30 May 2001 regarding public access to European Parliament, Council and Commission documents. Official Journal of the European Communities. 2001;L(145):43-48.
38.
European Medicines Agency: European medicines agency receives interim decisions of the general court of the EU on access to clinical and non-clinical information. 2013. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/04/news_detail_001779.jsp&mid=WC0b01ac058004d5c1 (accessed May 31, 2013).
39.
Doshi P, Jefferson T: The first 2 years of the European Medicines Agency's policy on access to documents: secret no longer. JAMA Intern Med 2013;173:380-382.
40.
European Medicines Agency: European Medicines Agency publishes final advice from clinical-trial advisory groups. 2013. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/04/news_detail_001778.jsp&mid=WC0b01ac058004d5c1 (accessed May 30, 2013).
41.
Action brought on 17 January 2013 - AbbVie e.a. v EMA. Official Journal of the European Union. 2013;C(79):26-27.
42.
Action brought on 11 February 2013 - InterMune UK and others v EMA. Official Journal of the European Union. 2013;C(114):38.
43.
AbbVie, Inc. v. EMA, Case T-44/13 (Gen. Ct., decided April 25, 2013).
44.
InterMune UK Ltd. v. EMA, Case T-73/13 R (Gen. Ct., decided April 25 2013).
45.
AllTrials: All Trials Registered, All Results Reported: medical researchers denied clinical trial information. 2013. http://www.alltrials.net/news/medical-researchers-denied-clinical-trial-information/ (accessed June 21, 2013).
46.
Cressey D: Clinical-trial transparency hits judicial roadblock, Nature Publishing Group. 2013. http://blogs.nature.com/news/2013/05/clinical-trial-transparency-hits-judicial-roadblock.html (accessed June 21, 2013).
47.
Pharmaceutical Research and Manufacturers of America (PhRMA): PhRMA statement on decision of the European General Court on EMA disclosure of company data. 2013. http://phrma.org/phrma-statement-on-decision-of-european-general-court-on-EMA-disclosure-of-company-data (accessed May 31, 2013).
48.
Rasi G: Clinical data: time for new approach. Financial Times http://www.ft.com/intl/cms/s/0/5c769724-adcb-11e2-82b8-00144feabdc0.html.
49.
AllTrials: All Trials Registered, All Results Reported: European Court injunction a huge backwards step. 2013. http://www.alltrials.net/news/1167-2/ (accessed June 12, 2013).
50.
Godlee F, Groves T: The new BMJ policy on sharing data from drug and device trials. BMJ 2012;345:e7888.
51.
BMJ: Helping doctors make better decisions: Open data. 2013. http://www.bmj.com/open-data (accessed June 27, 2013).
52.
AllTrials: All Trials Registered, All Results Reported: GSK statement. 2013. http://www.alltrials.net/supporters/gsk-statement/ (accessed June 21, 2013).
53.
GlaxoSmithKline: Clinical study register. http://www.gsk-clinicalstudyregister.com/ (accessed July 4, 2013).
54.
The Association of the British Pharmaceutical Industry (ABPI): ABPI statement on GSK signing up to the Alltrials campaign. 2013. http://www.abpi.org.uk/media-centre/newsreleases/2013/Pages/050213-b.aspx (accessed June 25, 2013).
55.
GlaxoSmithKline: TB or not TB. GSK gives update on plans to share detailed clinical trial data as part of its commitment to transparency. 2013. http://www.gsk.com/explore-gsk/how-we-do-r-and-d/TB-or-not-TB.html (accessed June 26, 2013).
56.
Butler D: GlaxoSmithKline goes public with malaria data, Nature Publishing Group. 2010. http://www.nature.com/news/2010/100120/full/news.2010.20.html (accessed July 3, 2013).
57.
Gamo FJ, Sanz LM, Vidal J, de Cozar C, Alvarez E, Lavandera JL, Vanderwall DE, Green DV, Kumar V, Hasan S, Brown JR, Peishoff CE, Cardon LR, Garcia-Bustos JF: Thousands of chemical starting points for antimalarial lead identification. Nature 2010;465:305-310.
58.
Jefferson T: Tamiflu cost us £424m yet we still don't know much about it. All Trials Registered, All Results Reported. 2013. http://www.alltrials.net/news/tamiflu-cost-us-424m-yet-we-still-dont-know-much-about-it/ (accessed June 27, 2013).
59.
BMJ: Helping doctors make better decisions: Tamiflu campaign. 2013. http://www.bmj.com/tamiflu (accessed June 27, 2013).
60.
Multiparty Group for Advice on Science (Mugas): Review and statistical analysis on Oseltamivir data. 2013. http://www.mugas.net/mugas/ (accessed June 27, 2013).
61.
BMJ: Helping doctors make better decisions: Roche agree to release all trial data on Tamiflu drug. 2013. http://www.bmj.com/press-releases/2013/04/04/roche-agree-release-all-trial-data-tamiflu-drug (accessed June 27, 2013).
62.
Cohen D: Roche offers researchers access to all Tamiflu trials. BMJ 2013;346:f2157.
63.
Medtronic: First-of-its-kind independent review of INFUSE® bone graft coordinated by Yale University is complete. 2013. http://newsroom.medtronic.com/phoenix.zhtml?c=251324&p=irol-newsArticle&ID=1830515 (accessed June 25, 2013).
64.
Bloomberg Businessweek: Medtronic slips after infuse reviews detailed. Associated Press. 2013. http://www.businessweek.com/ap/2013-06-18/medtronic-slips-after-infuse-reviews-detailed (accessed July 3, 2013).
65.
Beasley D: Medtronic bone graft has limited benefit, may cause harm-reviews. 2013. http://in.reuters.com/article/2013/06/17/medtronic-spine-graft-idINL2N0EP1WU20130617 (accessed June 27, 2013).
66.
Carragee EJ, Hurwitz EL, Weiner BK: A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. Spine J 2011;11:471-491.
67.
Yale School of Medicine: Center for outcomes research & evaluation: YODA project. http://medicine.yale.edu/core/projects/yodap/index.aspx (accessed June 28, 2013).
68.
Laine C, Goodman SN, Griswold ME, Sox HC: Reproducible research: moving toward research the public can really trust. Ann Intern Med 2007;146:450-453.
69.
Terry S: Rare disease day. Baby's first test. 2013. http://www.babysfirsttest.org/newborn-screening/blog/rare-disease-day (accessed June 27, 2013).
70.
U.S. Food and Drug Administration: Search orphan designations and approvals. http://www.accessdata.fda.gov/scripts/opdlisting/oopd/ (accessed June 27, 2013).
71.
European Commission: Register of designated Orphan Medicinal Products (by number). 2013. http://ec.europa.eu/health/documents/community-register/html/orphreg.htm (accessed June 25, 2013).
72.
GlaxoSmithKline: Data sharing agreement. 2013. https://clinicalstudydata.gsk.com/Documents/DATA%20SHARING%20AGREEMENT%20TEMPLATE%20for%20PATIENT%20LEVEL%20DATA%20ACCESS%20docx.pdf (accessed June 26, 2013).
73.
GlaxoSmithKline: GSK Clinical Study Requests. 2013. https://clinicalstudydata.gsk.com/ (accessed June 26, 2013).
© 2013 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
